Century Therapeutics (IPSC) Fundamental Analysis: Revenue, Earnings & Valuation

7.53 / 10

Outperform

Fundamental metrics indicate adequate status (7.5/10). Key strengths include a favorable PB-ROE, Asset-MV, and Cash-MV, alongside an impressive Gross profit margin of 100%. However, the Net profit / Total profit ratio of 100% falls into the lowest scoring group, and several turnover ratios are only moderate, tempering the overall outlook. This balance of robust and average factors results in an Outperform fundamental rating.

Analysis Checks(9/10)

Revenue-MV

Value-0.26

Score3/3

Weight27.52%

1M Return20.82%

Inventory turnover ratio

Value47.85

Score3/3

Weight4.70%

1M Return5.26%

Gross profit margin (%)

Value100.00

Score3/3

Weight10.74%

1M Return10.80%

Profit-MV

Value2.01

Score3/3

Weight17.08%

1M Return12.18%

PB-ROE

Value-0.87

Score3/3

Weight12.57%

1M Return11.47%

Current assets turnover ratio

Value0.66

Score2/3

Weight0.94%

1M Return1.15%

Fixed assets turnover ratio

Value1.35

Score2/3

Weight0.10%

1M Return0.12%

Asset-MV

Value-0.50

Score3/3

Weight18.57%

1M Return14.99%

Cash-MV

Value-0.07

Score2/3

Weight8.01%

1M Return7.73%

Net profit / Total profit (%)

Value100.00

Score0/3

Weight-0.24%

1M Return-0.30%

Is IPSC undervalued or overvalued?

IPSC scores 7.53/10 on fundamentals and holds a Discounted valuation at present. Backed by its 5.68% ROE, -23.37% net margin, -11.53 P/E ratio, 1.73 P/B ratio, and 82.51% earnings growth, these metrics solidify its Outperform investment rating.